Doctor Frías

AllAfrica

AllAfrica is a voice of, by and about Africa - aggregating, producing and distributing 1,200 news and information items daily from over 140 African news organizations and our own reporters to an African and global public. We operate from Cape Town, Dakar, Lagos, Monrovia, Nairobi and Washington DC.

© 2016 AllAfrica Privacy Contact


Liberia: 'Liberians Won't Be Used As Guinea Pigs' for Ebola Trial Drugs:


By Alaskai Moore Johnson

The Liberia Medicines & Health Products Regulatory Authority (LMHRA) has strongly warned pharmaceutical companies and others, who are trying to bring in "Ebola drugs/medicines," for trial purposes, that Liberians won't be used as Guinea pigs.

LMHRA, which released a statement yesterday, is the Government of Liberia's arm that has the statutory mandate to review and approve all clinical trials involving medicines and health products in the country.

The Health Products Regulatory body said that "while we are seeking for all the help needed to eradicate this virus, we also want to be very careful as to what medicines are brought into the country for treatment at our various ETUs."

In the wake of the deadly Ebola Virus Disease (EVD) outbreak in the country that has claimed the lives of thousands of Liberians and other nationals, LMHRA said many "unapproved and unlicensed medicines have begun to line up as trial treatments for Ebola virus disease (EVD) in the country. In the midst of this situation, it has become necessary that the process of clinical trials be properly guided by policies and procedures for the safeguard of the population."

The health regulatory body said it has been forced to speak out having read in a local newspaper that a purported Ebola treatment drug, Eboflip, has arrived in the country for trial on patients at ETUs.

"Eboflip, which is said to be indicated for the treatment of the Ebola Virus Disease, has no information on its pre-clinical safety data," LMHRA said.

Pre-clinical safety data, according to LMHRA, is when a drug has been pre-tested on a lower class animal like monkey and its data recorded before it can be tested on humans.

The LMHRA said for the Eboflip to be tested in Liberia, a "Clinical Trial Proposal" has to be submitted to it but "up to the time of this press statement, there has been no Clinical Trial Proposal submitted to the LMHRA. The LMHRA further stated that Chief Medical Officer, Dr. Bernice Dahn, whom the newspaper claims had given "authorization" for the drug trial, denied ever doing so.

The LMHRA Managing Director, Pharmacist David Sumo said: "We would like to use this medium to inform the Eurofarmacos that, there are procedures and guidelines for clinical trials that must be followed by any institution wishing to carry out any of such activities."

Eboflip is manufactured by Eurofarmacos Group Europe, a Spanish biotechnology company.

In a release posted on the company's website, it announced that 20 days ago, it "donated to the Government of Liberia, to carry out clinical trials of immediate form a novel anti-viral treatment against EBOLA, the “EBOFLIP”.

Eurofarmacos Group Europe's statement quotes its president, Dr. José Manuel Frias, as saying, "We don't have the slightest doubt that, in a record time of not more than 40 days, we will make public the news of the results obtained and if they are consistent enough to ensure ultimate control of the EBOLA pandemic."

Dr. Frias also disclosed that his company has currently prepared 30,000 treatments and has a production capacity of 500,000 monthly treatments.

"Fortunately, the news arriving from Liberia, not only affirm the effectiveness of the 'EBOFLIP', but they do it in just 15 days of treatment, which significantly increases the hope that this treatment if it is the solution to this pandemic, which keeps all countries of the world in check," Said Dr. Frias.

 

Liberia: New Ebola Drug in Town


Photo: WHO

A health professional treats an Ebola patient in Guinea.


However, what appears to be the much-desired relief has arrived; courtesy of the group, "Friends of Liberia in the Caribbean and Spain." The Analyst reports.

such as close family, treating doctors and medical staff," the group said.

Accepting the donation of drugs on behalf of the Government of Liberia, Dr. Bernice Dahn, Deputy Minister for Health Services and Chief Medical Officer at the Ministry of Health and Social Welfare, thanked Ambassador Johnson for the assistance to Liberia and asked him to convey to Ambassador Rafael Martinez and the Friends of Liberia in the Caribbean and Spain, especially the laboratories of Eurofármacos Group Europa S.L., that the Liberian people are extremely grateful for the donation, which has come at a critical time, when the country and its people are grappling with the Ebola Virus which is ravaging the lives of hundreds of our people.


It has been announced that an experimental drug to cure Ebola has arrived in the country. The Medicine, produced by a group of scientists from the laboratories of the Eurofármacos Group Europa based in Spain, sent the new antiviral treatment to Liberia, named "EBOFLIP", to start an immediate clinical trial on patients infected with the EBOLA virus.

The pronouncement is made by the Friends of Liberia in the Caribbean and Spain, led by Ambassador Rafael Martinez, which has again donated a second consignment of assorted Medicine to Liberia, to assist with the fight of the Ebola Virus.

Making the second donation at the Ministry of Health and Social Welfare this week, on behalf of Eurofarmacos Group, Liberia's former Ambassador to the Court of St. James, Ambassador Wesley Momo Johnson, said the drugs represent a form of treatment that is effective for viral infection in immune-competent and immune-compromised patients with Viral Hemorrhagic Fevers such as Ebola.

Amb. Johnson is now the Chief Executive Officer of Access Liberia Incorporated, a Liberian-owned consultant firm which represents the company in Liberia.

According to a press release quotes Dr. José Manuel Frias, President of Eurofármacos Group Europa that the manufacturer of EBOFLIP saying, "We have no doubt that within the next few weeks Liberia should able to affirm the results of the clinical trial of the drugs, and that they will prove consistent enough to ensure the ultimate control of the pandemic".

According to the release the Eurofármacos Group Europa already has 30,000 treatments in stock awaiting distribution and has the ability to produce up to 500,000 treatments per month if required.

The company also states that EBOFLIP, unlike other products being trialed at present, is not only effective at stopping the development of the disease, but also provides excellent immunity against contracting Ebola, without having to create a live vaccine solution for the virus.

"This is particularly important in immunizing those at high-risk of exposure to the virus
 

Liberian Observer (Monrovia) 

 

Liberia: 'Liberians Won't Be Used As Guinea Pigs' for Ebola Trial Drugs

ETUs.

"Eboflip, which is said to be indicated for the treatment of the Ebola Virus Disease,

The health regulatory body said it has been forced to speak out having read in a local newspaper that a purported Ebola treatment drug, Eboflip, has arrived in the country for trial on patients atno information on its pre-clinical safety data," LMHRA said.

Pre-clinical safety data, according to LMHRA, is when a drug has been pre-tested on a lower class animal like monkey and its data recorded before it can be tested on humans.

The LMHRA said for the Eboflip to be tested in Liberia, a "Clinical Trial Proposal" has to be submitted to it but "up to the time of this press statement, there has been no Clinical Trial Proposal submitted to the LMHRA. The LMHRA further stated that Chief Medical Officer, Dr. Bernice Dahn, whom the newspaper claims had given "authorization" for the drug trial, denied ever doing so.

The LMHRA Managing Director, Pharmacist David Sumo said: "We would like to use this medium to inform the Eurofarmacos that, there are procedures and guidelines for clinical trials that must be followed by any institution wishing to carry out any of such activities."

Eboflip is manufactured by Eurofarmacos Group Europe, a Spanish biotechnology company.

In a release posted on the company's website, it announced that 20 days ago, it "donated to the Government of Liberia, to carry out clinical trials of immediate form a novel anti-viral treatment against EBOLA, the 'EBOFLIP.'"

Eurofarmacos Group Europe's statement quotes its president, Dr. José Manuel Frias, as saying, "We don't have the slightest doubt that, in a record time of not more than 40 days, we will make public the news of the results obtained and if they are consistent enough to ensure ultimate control of the EBOLA pandemic."

Dr. Frias also disclosed that his company has currently prepared 30,000 treatments and has a production capacity of 500,000 monthly treatments.

"Fortunately, the news arriving from Liberia, not only affirm the effectiveness of the 'EBOFLIP', but they do it in just 15 days of treatment, which significantly increases the hope that this treatment if it is the solution to this pandemic, which keeps all countries of the world in check," Said Dr. Frias

 
Photo: WHO


A health professional treats an Ebola patient in Guinea.

 
Monrovia — Despite the massive outpour of material and human contributions from national and international sources, the Ebola Virus Disease is widely believed to be winning. In fact experts say it is they expect fatality of 10,000 every week in the next weeks in addition to the heartbreaking 1.4m infections in December and January. But with no proven clinical prove of cure, these predictions and actual infections are gloomier than what is likely to happen in this country. The desperately needed solution is ultimately Ebola's cure, which many pharmaceutical companies would not be ready as urgently and desperately needed on the ground.

However, what appears to be the much-desired relief has arrived; courtesy of the group, "Friends of Liberia in the Caribbean and Spain." The Analyst reports.

It has been announced that an experimental drug to cure Ebola has arrived in the country. The Medicine, produced by a group of scientists from the laboratories of the Eurofármacos Group Europa based in Spain, sent the new antiviral treatment to Liberia, named "EBOFLIP", to start an immediate clinical trial on patients infected with the EBOLA virus.

The pronouncement is made by the Friends of Liberia in the Caribbean and Spain, led by Ambassador Rafael Martinez, which has again donated a second consignment of assorted Medicine to Liberia, to assist with the fight of the Ebola Virus.

Making the second donation at the Ministry of Health and Social Welfare this week, on behalf of Eurofarmacos Group, Liberia's former Ambassador to the Court of St. James, Ambassador Wesley Momo Johnson, said the drugs represent a form of treatment that is effective for viral infection in immune-competent and immune-compromised patients with Viral Hemorrhagic Fevers such as Ebola.

Amb. Johnson is now the Chief Executive Officer of Access Liberia Incorporated, a Liberian-owned consultant firm which represents the company in Liberia.

According to a press release quotes Dr. José Manuel Frias, President of Eurofármacos Group Europa that the manufacturer of EBOFLIP saying, "We have no doubt that within the next few weeks Liberia should able to affirm the results of the clinical trial of the drugs, and that they will prove consistent enough to ensure the ultimate control of the pandemic".

According to the release the Eurofármacos Group Europa already has 30,000 treatments in stock awaiting distribution and has the ability to produce up to 500,000 treatments per month if required.

The company also states that EBOFLIP, unlike other products being trialed at present, is not only effective at stopping the development of the disease, but also provides excellent immunity against contracting Ebola, without having to create a live vaccine solution for the virus.

"This is particularly important in immunizing those at high-risk of exposure to the virus such as close family, treating doctors and medical staff," the group said.

Accepting the donation of drugs on behalf of the Government of Liberia, Dr. Bernice Dahn, Deputy Minister for Health Services and Chief Medical Officer at the Ministry of Health and Social Welfare, thanked Ambassador Johnson for the assistance to Liberia and asked him to convey to Ambassador Rafael Martinez and the Friends of Liberia in the Caribbean and Spain, especially the laboratories of Eurofármacos Group Europa S.L., that the Liberian people are extremely grateful for the donation, which has come at a critical time, when the country and its people are grappling with the Ebola Virus which is ravaging the lives of hundreds of our people.

She went on to praise the Eurofarmacos Group for the donation and promised to provide the Ebola Treatment Unit with the drug to ensure that it is clinically tested; in keeping with acceptable standards and that the results would be conveyed to the Lab accordingly.



19 DE OCTUBRE 2014

El Analista (Monrovia)

Liberia: Nueva Ébola Drogas en Ciudad


 
MÁS ACERCA DE ESTE

Ébola Drogas que se introducirá en Liberia, Guinea
 

Monrovia - A pesar de la outpour masiva de material y las contribuciones humanas de fuentes nacionales e internacionales, la Enfermedad por el virus del Ébola se cree estar ganando.De hecho los expertos dicen que es que esperan fatalidad de 10.000 cada semana en las próximas semanas, además de los 1,4 millones de infecciones desgarradoras en diciembre y enero. Pero sin probada clínica demuestran de cura, estas predicciones y las infecciones reales son más sombrío de lo que es probable que suceda en este país. La solución necesita desesperadamente es en última instancia, la cura de Ébola, que muchas compañías farmacéuticas no estarían listos como urgente y desesperadamente necesaria en el suelo.

Sin embargo, lo que parece ser el alivio tan deseada ha llegado;cortesía del grupo "Amigos de Liberia en el Caribe y España." Los informes de los analistas.

Se ha anunciado que un fármaco experimental para curar Ébola ha llegado al país. La Medicina, producido por un grupo de científicos de los laboratorios de la Eurofármacos Grupo Europa con sede en España, envió el nuevo tratamiento antiviral a Liberia, llamada «EBOFLIP", para iniciar un ensayo clínico inmediato en pacientes infectados con el virus del Ébola.

El pronunciamiento se hace por los Amigos de Liberia en el Caribe y España, encabezados por el Embajador Rafael Martínez, que ha donado más de un segundo lote de Medicina surtidos a Liberia, para ayudar en la lucha del virus Ébola.

Tomar la segunda donación del Ministerio de Salud y Bienestar Social de esta semana, en nombre de Eurofarmacos Group, ex Embajador de Liberia ante la Corte de St. James, el Embajador Wesley Momo Johnson, dijo que las drogas representan una forma de tratamiento que sea eficaz para viral infección en pacientes inmuno-competentes y inmunocomprometidos con Fiebres hemorrágicas virales como el Ébola.

Amb. Johnson es ahora el director general de Acceso Liberia Incorporated, una firma consultora de propiedad liberiana, que representa a la compañía en Liberia.

De acuerdo con un comunicado de prensa cita al Dr. José Manuel Frías, Presidente de Eurofármacos Grupo Europa de que el fabricante de EBOFLIP diciendo: "No tenemos ninguna duda de que en las próximas semanas Liberia debería poder afirmar los resultados del ensayo clínico de los medicamentos, y que van a demostrar lo suficientemente consistentes como para garantizar el máximo control de la pandemia ".

Según el comunicado de la Eurofármacos Grupo Europa ya cuenta con 30.000 tratamientos en stock distribución de espera y tiene la capacidad para producir hasta 500.000 tratamientos al mes si es necesario.

La compañía también afirma que EBOFLIP, a diferencia de otros productos que están probando en la actualidad, no sólo es eficaz en detener el desarrollo de la enfermedad, sino que también proporciona una excelente inmunidad contra contraer Ebola, sin tener que crear una solución de vacuna viva para el virus.

"Esto es particularmente importante en la inmunización de las personas con alto riesgo de exposición al virus, como familia cercana, el tratamiento de los médicos y el personal médico", dijo el grupo.

La aceptación de la donación de medicamentos en nombre del Gobierno de Liberia, el Dr. Bernice Dahn, Viceministro de Servicios de Salud y Director General de Salud del Ministerio de Salud y Bienestar Social, agradeció al Embajador Johnson para la asistencia a Liberia y le pidió transmitir a Embajador Rafael Martínez y los Amigos de Liberia en el Caribe y España, especialmente los laboratorios de Eurofármacos Grupo Europa SL, que el pueblo de Liberia están muy agradecidos por la donación, que ha llegado en un momento crítico, cuando el país y su gente están lidiando con el virus de Ébola que está causando estragos en las vidas de cientos de nuestros pueblos.

Ella pasó a alabar al Grupo Eurofarmacos para la donación y se comprometió a proporcionar a la Unidad de Tratamiento de Ebola con el medicamento para asegurarse de que está probado clínicamente;de acuerdo con las normas aceptables y que los resultados serían transportados al laboratorio en consecuencia.

 

EBOFLIP - ochranná známka, Majiteľ FRIAS JOSE MANUEL PENA

Kurzy " podnikání " Ochranné známky " FRIAS JOSE MANUEL PENA

Zájezdy | Last minute | počasí online | Bydlet | Obchodní rejstřík

Přihlášení

[Inglés version]

[Kurzy.cz - Akcie cz, kurzy měn, forex, zlato.]

středa 13.1.2016 8:43:36

Oblíbené: CZ Akcie Akcie svět Kurzy měn Komodity Zlato Forex zákony Kalkulačky Hypotéky Tarify Semináře Práce počasí

Základní údaje ochranné známky

- - - - - - -

Zdroj

OHIM

Číslo SPISU

13301551

EBOFLIP - Trademark, owner FRIAS JOSE MANUEL PENA

Courses »Business» Trademarks »JOSE MANUEL PENA FRIAS

Cruises | Last Minute | Weather Online | Live | Business index

Přihlášení

[English version]

[Kurzy.cz - Shares cz, exchange rates, forex, gold.]

středa 13.1.2016 8:45:59

Favorites: Shares E Shares of World Currency Rates Commodities Gold Forex Laws Calculators Mortgage Tariffs Seminars Jobs Weather

Basic data trademarks

- - - - - - -

Source

Office

File number

13301551

Reproduction / Text OZ

[EBOFLIP - trademark]
EBOFLIP

Class products and services

5, 35

Vienna image classes

03/05/13; 03/05/15; 05/03/11

Date of filing

September 26, 2014

Date of publication of the application

10/24/2014

Applicant / Holder

JOSE MANUEL FRIAS PEÑA 

Representative

GT. DE Propiedad Industrial, SL 



Mark consisting exclusively of color

CS red, blue, black.

Mark consisting exclusively of color

EN Red, blue, black.

Mark consisting exclusively of color

FR Rouge, bleu, noir.

State

Published Application

Species

Image

List of goods and services

5

Pharmaceutical products; Veterinary products; Sanitary preparations for medical purposes; Food for babies; Dietary and nutritional supplements; Plasters, materials for dressings. 

Produits pharmaceutiques; Produits vétérinaires; Hygiéniques produits pour la Médecine; Aliments pour bébés; Complements alimentaires et nutritionnels;Emplâtres, matériel pour pansements. 

Pharmaceutical Preparations; Veterinary preparations; Sanitary preparations for medical Purposes; Food for babies; Dietary and nutritional supplements; Plasters, materials for dressings. 

35

Business services and consumer information; Business analysis, research and information services; Advertising, marketing and promotional services. 

Services de negociations Commerciales d'information et de la clientèle; Services d'analyzes, de recherche et d'informations relatifs aux affaires; Services de publicité, de marketing et de promotion. 

Commercial trading and consumer information services; Business analysis, research and information services; Advertising, marketing and promotional services. 

EBOFLIP information to extract the mark

Extract data to a trademark EBOFLIP was taken on.

Original statement can be found at the Industrial Property Office, Czech version and English version

Declaración original se puede encontrar en la Oficina de Propiedad Industrial, versión checa y la versión Inglés